PREVENTION OF NEURAL TUBE DEFECTS BY IMMUNE STIMULATION

通过免疫刺激预防神经管缺陷

基本信息

  • 批准号:
    6931536
  • 负责人:
  • 金额:
    $ 10.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2008-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dr. Terry Hrubec received the D.V.M. and Ph.D. degrees and is embarking on a research career. She is a highly motivated scientist who wishes to make a career shift from clinical pathology and immunology of aquatic species to research in mammalian cellular and molecular immunology. This award would offer Dr. Hrubec an opportunity to strengthen and expand research skills by affording training in molecular mechanisms of developmental abnormalities and using animal models of human disease. The proposed research investigates the mechanism by which maternal immune stimulation prevents valproic acid (VA) induced birth defects. VA, a drug commonly used to treat epilepsy, is teratogenic and induces neural tube defects (NTDs) in one to two percent of exposed fetuses at a rate 20 times higher than in the general population. In what the investigators feel is paradigm-changing work, data from the investigators' laboratory have conclusively demonstrated that non-specific activation of the maternal immune system in rodents can dramatically reduce a variety of chemical-induced birth defects, including VA induced NTDs. Additionally, the investigators have shown that such maternal immune stimulation normalizes teratogen-altered expression of a few selected fetal cell-cycle/apoptotic regulatory genes in urethane-induced cleft palate. A more focused examination of altered gene expression in VA induced NTDs is now logical. Specifically, the investigators will test the hypotheses that: 1) VA affects the expression of genes regulating neural tube development, and that maternal immune stimulation normalizes gene expression through regulatory proteins (cytokines) secreted by activated immune cells; and 2) folic acid supplementation protects against NTDs by cytokine-related mechanisms which may in part be similar to that resulting after maternal immune stimulation. These studies are expected to significantly increase the investigators' understanding of genetic mechanisms by which maternal immune modulation reduces this specific birth defect. Clearly, this research is of importance to human health, as determining the mechanisms involved will improve the understanding of this disorder leading to a prevention or cure. This research will be conducted under the guidance of Drs. Steven Holladay and Ansar Ahmed of the Virginia-Maryland Regional College of Veterinary Medicine at the VPISU, and will offer excellent training and career development for Dr. Hrubec.
描述(由申请人提供):Terry Hrubec博士收到了D.V.M.和博士学位,并开始了研究生涯。 她是一位积极进取的科学家,希望从水生物种的临床病理学和免疫学转向哺乳动物细胞和分子免疫学的研究。 该奖项将为Hrubec博士提供一个机会,通过提供发育异常分子机制的培训和使用人类疾病的动物模型来加强和扩大研究技能。 本研究旨在探讨母体免疫刺激预防丙戊酸(VA)诱导的出生缺陷的机制。 VA是一种常用于治疗癫痫的药物,具有致畸性,在1%至2%的暴露胎儿中诱导神经管缺陷(NTD),其发生率比一般人群高20倍。 在研究人员认为是改变范式的工作中,来自研究人员实验室的数据最终证明,啮齿动物母体免疫系统的非特异性激活可以显着减少各种化学诱导的出生缺陷,包括VA诱导的NTD。 此外,研究人员已经表明,这种母体免疫刺激使胎儿诱导的腭裂中一些选定的胎儿细胞周期/凋亡调控基因的致畸原改变表达正常化。 现在,对VA诱导的NTD中基因表达改变进行更集中的检查是合乎逻辑的。 具体而言,研究人员将测试以下假设:1)VA影响调节神经管发育的基因表达,并且母体免疫刺激通过激活的免疫细胞分泌的调节蛋白(细胞因子)使基因表达正常化;和2)叶酸补充剂通过精氨酸相关机制保护NTD,这可能部分类似于母体免疫刺激后产生的机制。 这些研究有望显著增加研究人员对母体免疫调节减少这种特定出生缺陷的遗传机制的理解。 显然,这项研究对人类健康具有重要意义,因为确定所涉及的机制将提高对这种疾病的理解,从而预防或治愈。 这项研究将在VPISU马里兰州兽医区域学院的Steven Holladay和Ansar Ahmed博士的指导下进行,并将为Hrubec博士提供出色的培训和职业发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THERESA C HRUBEC其他文献

THERESA C HRUBEC的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THERESA C HRUBEC', 18)}}的其他基金

Birth Defects in Mice Caused by Tap Water
自来水导致小鼠出生缺陷
  • 批准号:
    8004103
  • 财政年份:
    2010
  • 资助金额:
    $ 10.8万
  • 项目类别:
Birth Defects in Mice Caused by Tap Water
自来水导致小鼠出生缺陷
  • 批准号:
    7788635
  • 财政年份:
    2010
  • 资助金额:
    $ 10.8万
  • 项目类别:
PREVENTION OF NEURAL TUBE DEFECTS BY IMMUNE STIMULATION
通过免疫刺激预防神经管缺陷
  • 批准号:
    7102665
  • 财政年份:
    2003
  • 资助金额:
    $ 10.8万
  • 项目类别:
PREVENTION OF NEURAL TUBE DEFECTS BY IMMUNE STIMULATION
通过免疫刺激预防神经管缺陷
  • 批准号:
    6530524
  • 财政年份:
    2003
  • 资助金额:
    $ 10.8万
  • 项目类别:
PREVENTION OF NEURAL TUBE DEFECTS BY IMMUNE STIMULATION
通过免疫刺激预防神经管缺陷
  • 批准号:
    7269446
  • 财政年份:
    2003
  • 资助金额:
    $ 10.8万
  • 项目类别:
PREVENTION OF NEURAL TUBE DEFECTS BY IMMUNE STIMULATION
通过免疫刺激预防神经管缺陷
  • 批准号:
    6801852
  • 财政年份:
    2003
  • 资助金额:
    $ 10.8万
  • 项目类别:

相似海外基金

The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
  • 批准号:
    23K14967
  • 财政年份:
    2023
  • 资助金额:
    $ 10.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
  • 批准号:
    10644811
  • 财政年份:
    2023
  • 资助金额:
    $ 10.8万
  • 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
  • 批准号:
    10724185
  • 财政年份:
    2023
  • 资助金额:
    $ 10.8万
  • 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
  • 批准号:
    10725869
  • 财政年份:
    2023
  • 资助金额:
    $ 10.8万
  • 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
  • 批准号:
    10633548
  • 财政年份:
    2023
  • 资助金额:
    $ 10.8万
  • 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
  • 批准号:
    10480649
  • 财政年份:
    2022
  • 资助金额:
    $ 10.8万
  • 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
  • 批准号:
    22K20740
  • 财政年份:
    2022
  • 资助金额:
    $ 10.8万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
  • 批准号:
    10616658
  • 财政年份:
    2022
  • 资助金额:
    $ 10.8万
  • 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
  • 批准号:
    10040788
  • 财政年份:
    2020
  • 资助金额:
    $ 10.8万
  • 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
  • 批准号:
    10250486
  • 财政年份:
    2020
  • 资助金额:
    $ 10.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了